Ribomic Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Ribomic's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been declining at an average rate of 8% per year.
Wichtige Informationen
-9.2%
Wachstumsrate der Gewinne
6.8%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 31.9% |
| Wachstumsrate der Einnahmen | -8.0% |
| Eigenkapitalrendite | -29.8% |
| Netto-Marge | -94,400.0% |
| Nächste Ertragsaktualisierung | 12 Nov 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Ribomic Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -944 | 349 | 687 |
| 31 Mar 24 | 0 | -1,024 | 352 | 764 |
| 31 Dec 23 | 62 | -979 | 350 | 816 |
| 30 Sep 23 | 62 | -1,329 | 377 | 1,126 |
| 30 Jun 23 | 63 | -1,374 | 367 | 1,189 |
| 31 Mar 23 | 65 | -1,653 | 361 | 1,491 |
| 31 Dec 22 | 76 | -2,046 | 331 | 1,846 |
| 30 Sep 22 | 78 | -1,795 | 324 | 1,618 |
| 30 Jun 22 | 80 | -1,961 | 324 | 1,767 |
| 31 Mar 22 | 80 | -1,684 | 313 | 1,482 |
| 31 Dec 21 | 93 | -1,448 | 282 | 1,268 |
| 30 Sep 21 | 92 | -1,366 | 270 | 1,207 |
| 30 Jun 21 | 91 | -1,255 | 286 | 1,049 |
| 31 Mar 21 | 91 | -1,187 | 304 | 957 |
| 31 Dec 20 | 121 | -1,056 | 337 | 839 |
| 30 Sep 20 | 122 | -1,044 | 332 | 823 |
| 30 Jun 20 | 122 | -903 | 325 | 710 |
| 31 Mar 20 | 121 | -855 | 319 | 673 |
| 31 Dec 19 | 12 | -804 | 342 | 580 |
| 30 Sep 19 | 10 | -761 | 332 | 543 |
| 30 Jun 19 | 8 | -779 | 327 | 562 |
| 31 Mar 19 | 7 | -836 | 322 | 612 |
| 31 Dec 18 | 14 | -919 | 324 | 748 |
| 30 Sep 18 | 30 | -904 | 315 | 759 |
| 30 Jun 18 | 47 | -867 | 307 | 746 |
| 31 Mar 18 | 64 | -753 | 300 | 663 |
| 31 Dec 17 | 68 | -714 | 285 | 604 |
| 30 Sep 17 | 77 | -700 | 283 | 621 |
| 30 Jun 17 | 86 | -661 | 282 | 599 |
| 31 Mar 17 | 93 | -646 | 268 | 610 |
| 31 Dec 16 | 101 | -459 | 254 | 521 |
| 30 Sep 16 | 103 | -393 | 241 | 453 |
| 30 Jun 16 | 106 | -371 | 225 | 455 |
| 31 Mar 16 | 121 | -323 | 219 | 435 |
| 31 Dec 15 | 149 | -365 | 217 | 334 |
| 30 Sep 15 | 173 | -317 | 213 | 313 |
| 30 Jun 15 | 197 | -286 | 213 | 291 |
| 31 Mar 15 | 479 | 10 | 191 | 282 |
| 31 Mar 14 | 151 | -211 | 146 | 418 |
Qualität der Erträge: 4591 is currently unprofitable.
Wachsende Gewinnspanne: 4591 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 4591 is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.
Beschleunigtes Wachstum: Unable to compare 4591's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 4591 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 4591 has a negative Return on Equity (-29.75%), as it is currently unprofitable.